• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000153.SZ
Share

Anhui Fengyuan Pharmaceutical Co., Ltd. Stocks

CN¥ 5.51Last Updated 14.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

CN¥ 376.50M

CN¥ 5.51
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in Hefei, China in 1997, Anhui Fengyuan Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of a wide array of medicinal products. The company primarily serves the Chinese market, offering biological pharmaceuticals, chemical drugs, and traditional Chinese medicines. Its extensive product portfolio addresses numerous health concerns, including pain and fever relief, cardiovascular conditions, infections, neurological disorders, cancer, ulcers, and hormonal imbalances. Fengyuan Pharmaceutical also produces nutritional supplements, treatments for vitamin and mineral deficiencies, anti-parasitic and antimicrobial agents, coenzymes, antiviral medications, and uterine contractants. Furthermore, its offerings encompass sedative-hypnotics, drugs for irritable bowel syndrome, hypertension treatments, and remedies for benign prostatic hyperplasia. Beyond its domestic operations, the company exports its pharmaceutical goods to international markets such as Europe, North America, Africa, Southeast Asia, and Central Asia.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 11:45

HSBC has named Kaspi shares its top pick for July. Why does it expect them to rise by a third?

15.07.2026 11:26

PayPal Shares Surge: Fintech Giant Stripe Offers to Buy It — Reuters

15.07.2026 11:00

China's GDP growth has slowed to a three-year low. What can we expect from Beijing?

15.07.2026 10:25

Morning Roundup: IBM's Worst Day, Stripe Sets Its Sights on PayPal, and an OpenAI Gadget

15.07.2026 09:30

Goldman Sachs: The AI boom has reached the same scale as the dot-com boom, but is following a different trajectory

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026